keyword
MENU ▼
Read by QxMD icon Read
search

Statins use in ckd

keyword
https://www.readbyqxmd.com/read/28065770/risk-of-colchicine-associated-myopathy-in-gout-influence-of-concomitant-use-of-statin
#1
Oh Chan Kwon, Seokchan Hong, Byeongzu Ghang, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo
OBJECTIVE: To investigate the risk of myopathy when statins are coadministered with colchicine in patients with gout. METHODS: In gout patients who received colchicine with or without statin, clinical data collected included medications and history of hypertension, chronic kidney disease, and liver cirrhosis. Myopathy was defined as the presence of muscle symptoms with elevated creatinine phosphokinase and/or myoglobin. Multivariate analysis was performed to identify risk factors for myopathy...
January 5, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28056847/impact-of-diabetes-and-hypertension-on-cardiovascular-outcomes-in-patients-with-coronary-artery-disease-receiving-percutaneous-coronary-intervention
#2
Mao-Jen Lin, Chun-Yu Chen, Hau-De Lin, Han-Ping Wu
BACKGROUND: Percutaneous coronary intervention (PCI) is a necessary procedure commonly performed for patients with coronary artery disease (CAD). However, the impact of diabetes and hypertension on long-term outcomes of patients after receiving PCI has not yet been determined. METHODS: The data of 1234 patients who received PCI were collected prospectively, and patients were divided into four groups, including patients with and without DM and those with either DM or hypertension alone...
January 5, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28036114/does-statins-promote-vascular-calcification-in-chronic-kidney-disease
#3
Zhimin Chen, Abdul Rashid Qureshi, Paolo Parini, Eva Hurt-Camejo, Jonaz Ripsweden, Torkel B Brismar, Peter Barany, Armand Jaminon, Leon J Schurgers, Olof Heimburger, Bengt Lindholm, Peter Stenvinkel
BACKGROUND: In end-stage renal disease (ESRD), coronary artery calcification (CAC) and inflammation contribute to cardiovascular disease (CVD). Statins do not improve survival in ESRD patients and their effect on vascular calcification is unclear. We explored associations between CAC, inflammatory biomarkers, statins and mortality in ESRD. MATERIAL AND METHODS: In 240 ESRD patients (63% males; median age 56 years) from cohorts including 86 recipients of living donor kidney transplant (LD-Rtx), 96 incident dialysis patients and 58 prevalent peritoneal dialysis patients, associations of CAC score (Agatston Units, AUs), interleukin-6 (IL-6) with high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor (TNF), use of statins and all-cause mortality were analysed...
December 30, 2016: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28000009/dyslipidemia-in-patients-with-chronic-kidney-disease
#4
REVIEW
Matthew R Hager, Archana D Narla, Lisa R Tannock
Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels...
December 20, 2016: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/27960010/-lipid-metabolism-abnormalities-in-chronic-kidney-disease
#5
Stefano Bianchi, Alessandro Baronti, Renato Cominotto, Roberto Bigazzi
Regardless of the etiology of renal disease, patients with chronic kidney disease (CKD) develop profound qualitative and quantitative lipoprotein metabolism abnormalities because of the presence of alterations in apolipoproteins, lipid transfer proteins, lipolytic enzymes, and lipoprotein receptors from the earlier stages of the disease. As renal function deteriorates, triglyceride concentrations increase and high-density lipoprotein cholesterol (HDL) concentrations decline, while levels of low- density lipoprotein (LDL) cholesterol remain in the normal range or become slightly decreased...
2016: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/27921039/clinical-manifestation-and-management-of-adpkd-in-western-countries
#6
REVIEW
Claudia Sommerer, Martin Zeier
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease in Western countries. The prevalence is between 2.4/10,000 and 3.9/10,000. ADPKD represents a systemic disease resulting in deterioration in renal function. Until now, mutations in two genes (PKD1 and PKD2) have been identified. Recently, the European Medicines Agency (EMA) approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency connected with ADPKD in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease...
October 2016: Kidney Diseases
https://www.readbyqxmd.com/read/27867158/preprocedural-high-sensitivity-c-reactive-protein-predicts-long-term-outcome-of-percutaneous-coronary-intervention
#7
Hideki Wada, Tomotaka Dohi, Katsumi Miyauchi, Jun Shitara, Hirohisa Endo, Shinichiro Doi, Ryo Naito, Hirokazu Konishi, Shuta Tsuboi, Manabu Ogita, Takatoshi Kasai, Ahmed Hassan, Shinya Okazaki, Kikuo Isoda, Kazunori Shimada, Satoru Suwa, Hiroyuki Daida
BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) has been used to predict the risk of adverse cardiac events in patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI). Less is known, however, about the association between hs-CRP and long-term outcome after PCI in the Japanese population.Methods and Results:We studied 3,039 all-comer patients with CAD who underwent their first PCI and had data available for preprocedural hs-CRP at Juntendo University between 2000 and 2011...
December 22, 2016: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/27831597/pharmacological-management-of-dyslipidemia-in-high-and-very-high-cardiovascular-risk-patients
#8
V Pascual Fuster
Dyslipaemia is one of the main risk factors in the development of cardiovascular diseases. Currently, there are different alternatives available (amongst which statins occupy a pre-eminent place), to optimise the treatment of patients at high or very high cardiovascular risk. Despite this, the percentage of patients that achieve good lipid control is low. The causes of the mismatch with proposed objectives include lack of patient adherence and therapeutic inertia. This review uses available evidence and the latest clinical guides as a basis to assess the pharmacological treatment of dyslipaemia in patients with a background of arteriosclerotic vascular disease, diabetes, chronic kidney disease, cardiovascular risk at ≥5% calculated by SCORE and familial hypercholesterolaemia...
December 2016: Revista Española de Sanidad Penitenciaria
https://www.readbyqxmd.com/read/27825313/using-pharmacists-to-improve-risk-stratification-and-management-of-stage-3a-chronic-kidney-disease-a-feasibility-study
#9
Alex R Chang, Michael Evans, Christina Yule, Larissa Bohn, Amanda Young, Meredith Lewis, Elisabeth Graboski, Bethany Gerdy, William Ehmann, Jonathan Brady, Leah Lawrence, Natacha Antunes, Jamie Green, Susan Snyder, H Lester Kirchner, Morgan Grams, Robert Perkins
BACKGROUND: Measurement of albuminuria to stratify risk in chronic kidney disease (CKD) is not done universally in the primary care setting despite recommendation in KDIGO (Kidney Disease Improving Global Outcomes) guidelines. Pharmacist medication therapy management (MTM) may be helpful in improving CKD risk stratification and management. METHODS: We conducted a pragmatic, cluster-randomized trial using seven primary care clinic sites in the Geisinger Health System to evaluate the feasibility of pharmacist MTM in patients with estimated glomerular filtration rate (eGFR) 45-59 ml/min/1...
November 8, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/27749383/improving-treatment-for-patients-with-chronic-kidney-disease
#10
Kendra Thomsen, Kim Zuber, Jane Davis, Greg Thomas
OBJECTIVE: Kidneys in a Box (KIB) was developed to identify the effect of a performance improvement CME (PI-CME) project on the management of patients with diabetes who are at risk for chronic kidney disease (CKD). The program provided nonnephrology practitioners with research-based interventions known to slow CKD progression. METHODS: PAs were given the KIB tool kit, which described the scope of CKD identified high-risk diagnoses such as diabetes, and listed six modifiable risk factors that have been shown to slow progression of diabetic kidney disease when implemented...
November 2016: JAAPA: Official Journal of the American Academy of Physician Assistants
https://www.readbyqxmd.com/read/27729238/associations-between-cardiovascular-disease-risk-factors-and-il-6-and-hscrp-levels-in-the-elderly
#11
Paweł Nadrowski, Jerzy Chudek, Michał Skrzypek, Monika Puzianowska-Kuźnicka, Małgorzata Mossakowska, Andrzej Więcek, Tomasz Zdrojewski, Tomasz Grodzicki, Krystyna Kozakiewicz
BACKGROUND: Age-related diseases, including cardiovascular diseases (CVD) may be stimulated by microinflammation, marked by increased level of IL-6 and high-sensitivity CRP (hsCRP). We aimed to investigate whether aging "per se" independently contributesto themicroinflammation,inadditionto traditional and novel CVD risk factors. METHODS/RESULTS: The research sample included 4979 participants from PolSenior Study, aged over 65years. The study consisted of threevisitsandincludedquestionnairesurvey,geriatricassessmentandblood/urinesamplingin4101 participants (83...
October 8, 2016: Experimental Gerontology
https://www.readbyqxmd.com/read/27729086/low-and-exacerbated-levels-of-1-5-anhydroglucitol-are-associated-with-cardiovascular-events-in-patients-after-first-time-elective-percutaneous-coronary-intervention
#12
Shuhei Takahashi, Kazunori Shimada, Katsumi Miyauchi, Tetsuro Miyazaki, Eiryu Sai, Manabu Ogita, Shuta Tsuboi, Hiroshi Tamura, Shinya Okazaki, Tomoyuki Shiozawa, Shohei Ouchi, Tatsuro Aikawa, Tomoyasu Kadoguchi, Hamad Al Shahi, Takuma Yoshihara, Makoto Hiki, Kikuo Isoda, Hiroyuki Daida
BACKGROUND: Postprandial hyperglycemia plays an important role in the pathogenesis of coronary artery disease and cardiovascular events. Serum 1,5-anhydroglucitol (1,5-AG) levels are known to be a clinical marker of postprandial hyperglycemia. However, the impact of 1,5-AG level on cardiovascular events has not been fully investigated. METHODS: We enrolled 240 consecutive patients who had undergone first-time elective percutaneous coronary intervention (PCI) with follow-up angiography within 1 year...
October 11, 2016: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/27720344/long-term-outcomes-of-hepatitis-b-virus-related-cirrhosis-treated-with-nucleos-t-ide-analogs
#13
Ming-Chao Tsai, Chien-Hung Chen, Tsung-Hui Hu, Sheng-Nan Lu, Chuan-Mo Lee, Jing-Houng Wang, Chao-Hung Hung
BACKGROUND/PURPOSE: This study aimed to evaluate the outcomes of chronic hepatitis B patients with cirrhosis who received long-term nucleos(t)ide analog therapy. METHODS: A total of 546 consecutive cirrhotic patients treated with entecavir (n = 359), telbivudine (n = 104), or tenofovir (n = 83) for chronic hepatitis B were enrolled. The incidence of hepatocellular carcinoma (HCC) and overall survival were evaluated. RESULTS: During a median follow-up of 39 months, 56 (10...
October 5, 2016: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/27712954/2016-canadian-cardiovascular-society-guidelines-for-the-management-of-dyslipidemia-for-the-prevention-of-cardiovascular-disease-in-the-adult
#14
Todd J Anderson, Jean Grégoire, Glen J Pearson, Arden R Barry, Patrick Couture, Martin Dawes, Gordon A Francis, Jacques Genest, Steven Grover, Milan Gupta, Robert A Hegele, David C Lau, Lawrence A Leiter, Eva Lonn, G B John Mancini, Ruth McPherson, Daniel Ngui, Paul Poirier, John L Sievenpiper, James A Stone, George Thanassoulis, Richard Ward
Since the publication of the 2012 guidelines new literature has emerged to inform decision-making. The 2016 guidelines primary panel selected a number of clinically relevant questions and has produced updated recommendations, on the basis of important new findings. In subjects with clinical atherosclerosis, abdominal aortic aneurysm, most subjects with diabetes or chronic kidney disease, and those with low-density lipoprotein cholesterol ≥ 5 mmol/L, statin therapy is recommended. For all others, there is an emphasis on risk assessment linked to lipid determination to optimize decision-making...
July 25, 2016: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/27697414/delphi-consensus-on-the-diagnosis-and-management-of-dyslipidaemia-in-chronic-kidney-disease-patients-a-post-hoc-analysis-of-the-diana-study
#15
Aleix Cases Amenós, Juan Pedro-Botet Montoya, Vicente Pascual Fuster, Vivencio Barrios Alonso, Xavier Pintó Sala, Juan F Ascaso Gimilio, Jesús Millán Nuñez-Cortés, Adalberto Serrano Cumplido
BACKGROUND AND OBJECTIVES: This post hoc study analysed the perception of the relevance of chronic kidney disease (CKD) in dyslipidaemia screening and the choice of statin among primary care physicians (PCPs) and other specialists through a Delphi questionnaire. METHODS: The questionnaire included 4blocks of questions concerning dyslipidaemic patients with impaired carbohydrate metabolism. This study presents the results of the impact of CKD on screening and the choice of statin...
November 2016: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/27695357/update-on-current-management-of-chronic-kidney-disease-in-patients-with-hiv-infection
#16
REVIEW
Nina E Diana, Saraladevi Naicker
The prevalence of HIV-associated chronic kidney disease (CKD) varies geographically and depends on the definition of CKD used, ranging from 4.7% to 38% globally. The incidence, however, has decreased with the use of effective combined antiretroviral therapy (cART). A wide variety of histological patterns are seen in HIV-associated kidney diseases that include glomerular and tubulointerstitial pathology. In resource-rich settings, there has been a plateau in the incidence of end-stage renal disease secondary to HIV-associated nephropathy (HIVAN)...
2016: International Journal of Nephrology and Renovascular Disease
https://www.readbyqxmd.com/read/27664802/influence-of-late-vascular-inflammation-on-long-term-outcomes-among-patients-undergoing-implantation-of-drug-eluting-stents-role-of-c-reactive-protein
#17
Masanori Shiba, Hideki Itaya, Raisuke Iijima, Masato Nakamura
BACKGROUND: Elevation of C-reactive protein (CRP) as a marker of vascular inflammation at a late phase of drug-eluting stent (DES) implantation may predict subsequent major adverse cardiac events (MACE). METHODS AND RESULTS: In 1234 consecutive patients undergoing DES implantation, CRP was measured both before (baseline) and 8 to 12 months after (late phase) stenting, and the relationship between elevation of CRP (>2.0 mg/L) and subsequent MACE (all cause death, nonfatal myocardial infarction, target lesion revascularization, and other additional revascularization) was assessed...
2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27660844/statins-in-chronic-kidney-disease-when-and-when-not-to-use-them
#18
Nosratola D Vaziri, Deborah A Anzalone, Julia Catini
This supplement reviews the evidence from clinical trials for the appropriate use of statins in patients with Chronic kidney disease (CKD).
August 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/27650472/combination-drug-versus-monotherapy-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease
#19
Jacek Rysz, Anna Gluba-Brzózka, Beata Franczyk, Maciej Banach, Piotr Bartnicki
INTRODUCTION: Despite progress in the understanding of pathogenetic mechanisms of organ cyst formation in autosomal dominant polycystic kidney disease, current treatment methods are insufficient. Experimental studies and clinical trials target at inhibition of cysts development and to slowing CKD progression. AREAS COVERED: The purpose of this analysis is to overview available literature regarding treatment of ADPKD. The most important recent events concerning ADPKD treatment are: the results of TEMPO 3/4 study and the registration of tolvaptan in the treatment of patients with CKD stage I-III and rapidly progressive ADPKD by EMA...
October 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27456102/chronic-kidney-disease-and-cardiovascular-risk-modification
#20
Jerry Fan, Hasan Salameh
BACKGROUND: Chronic kidney disease (CKD) accounts for a significant proportion of the morbidity and mortality in the United States. CKD is defined as glomerular filtration rate (GFR) <60ml/min/1.73m2 or clear evidence of renal damage from biopsy. All-cause cardiovascular risk increases with decreasing GFR. Clinically, detection of CKD is through changes in creatinine clearance which estimates GFR, an indicator of kidney function. We reviewed conventional and nonconventional cardiovascular risk factors associated with CKD...
July 22, 2016: Current Vascular Pharmacology
keyword
keyword
118243
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"